Attached files
| file | filename |
|---|---|
| 10-K - ANNUAL REPORT - CHINA PHARMA HOLDINGS, INC. | f10k2020_chinapharma.htm |
| EX-31.2 - CERTIFICATION - CHINA PHARMA HOLDINGS, INC. | f10k2020ex31-2_chinapharm.htm |
| EX-31.1 - CERTIFICATION - CHINA PHARMA HOLDINGS, INC. | f10k2020ex31-1_chinapharm.htm |
| EX-23.1 - CONSENT OF THE INDEPENDENT ACCOUNTING FIRM. - CHINA PHARMA HOLDINGS, INC. | f10k2020ex23-1_chinapharm.htm |
| EX-10.10 - LOANS EXTENSION CONFIRMATION LETTER, DATED DECEMBER 31, 2020, BETWEEN THE COMPAN - CHINA PHARMA HOLDINGS, INC. | f10k2020ex10-10_chinapharm.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned hereby certifies, in her capacity as principal executive officer of China Pharma Holdings, Inc. (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:
(1) The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: March 26, 2021
| /s/ Zhilin Li | ||
| Name: | Zhilin Li | |
| President and Chief Executive Officer | ||
| (principal executive officer) | ||
| /s/ Zhilin Li | ||
| Name: | Zhilin Li | |
| Title: | Interim Chief Financial Officer | |
| (principal financial officer and principal accounting officer) | ||
This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.